Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stefanou, A.
Right arrow Articles by Dooley, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stefanou, A.
Right arrow Articles by Dooley, M.
Related Articles
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 21, Issue 10 (May), 2003: 2044
© 2003 American Society for Clinical Oncology


CORRESPONDENCE

Simple Method to Eliminate the Risk of Inadvertent Intrathecal Vincristine Administration

Angela Stefanou, Michael Dooley

Peter MacCallum Cancer Centre, Victoria, Australia

To the Editor: There are many reports of incidents of inadvertent intrathecal administration of vincristine, the earliest dating back to 1978 and the most recent in 2002.1–3 One of the many outcomes described by Womer et al4 of their systems for inpatient chemotherapy administration was a set of rules for minimizing the risk of intrathecal vincristine administration. The consequence of intrathecal vincristine administration is devastating, and as these authors and others have highlighted, it has occurred at many institutions throughout the world.

The strategy described by Womer et al4 to minimize this risk is not sufficient, as complete elimination is warranted and possible. The preparation of vincristine for intravenous bolus administration in a small-volume intravenous bag, as opposed to a syringe, is the only method of completely eradicating the risk of this drug accidentally being given intrathecally. This method of preparation is a practice that has been adopted not only at our institution, but also at the majority of hospitals in Australia. All published reports of intrathecal vincristine administration have been associated with preparation of the drug in a syringe.

In adults, vincristine is prepared in a small-volume intravenous bag containing 50 mL of sodium chloride 0.9%. This is administered as a short intravenous bolus for 5 to 10 minutes. For pediatric patients, the same approach is used but with a smaller volume of fluid in the infusion bag and a slower rate of administration.

We believe that this method of diluting vincristine for intravenous bolus-dosing into a small-volume intravenous bag, rather than in a syringe, is a simple method of eradicating the risk of catastrophic inadvertent intrathecal administration of vincristine.

REFERENCES

1. Shepherd DA, Steuber CP, Starling KA, et al: Accidental intrathecal administration of vincristine. Med Pediatr Oncol 5:85–88, 1978[Medline]

2. Alcaraz A, Rey C, Concha A, et al: Intrathecal vincristine: Fatal myeloencephalopathy despite cerebrospinal fluid perfusion. J Toxicol Clin Toxicol 40:557–561, 2002[CrossRef][Medline]

3. Dyer C: Doctors suspended after injecting wrong drug into spine. BMJ 322:257–258, 2001[Free Full Text]

4. Womer RB, Tracy E, Soo-Hoo W, et al: Multidisciplinary systems approach to chemotherapy safety: Rebuilding processes and holding the gains. J Clin Oncol 20:4705–4712, 2002[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

  • In Reply:
    Richard B. Womer and Betsy Bickert
    JCO 2003 21: 2044 [Full Text]


This article has been cited by other articles:


Home page
J Oncol Pharm PractHome page
P. J Gilbar and C. V Carrington
The incidence of extravasation of vinca alkaloids supplied in syringes or mini-bags
Journal of Oncology Pharmacy Practice, June 1, 2006; 12(2): 113 - 118.
[Abstract] [PDF]


Home page
J Oncol Pharm PractHome page
P. Gilbar, M. Dooley, and J.-a. Brien
Inadvertent intrathecal administration of vincristine: are we fulfilling our roles as oncology pharmacists?
Journal of Oncology Pharmacy Practice, December 1, 2004; 10(4): 187 - 189.
[PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stefanou, A.
Right arrow Articles by Dooley, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stefanou, A.
Right arrow Articles by Dooley, M.
Related Articles
Right arrowRelated Article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2003 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online